Cite
HARVARD Citation
Larkin, J. et al. (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European journal of cancer. pp. 285-296. [Online].